Literature DB >> 19735264

PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma.

Ali Fendri1, Abdelmajid Khabir, Wafa Mnejja, Tahia Sellami-Boudawara, Jamel Daoud, Mounir Frikha, Abdelmonem Ghorbel, Ali Gargouri, Raja Mokdad-Gargouri.   

Abstract

PI3Ks (phosphatidylinositol 3-kinases) are lipid kinases that regulate signalling pathways involved in cell proliferation, motility, and adhesion. Somatic mutations and amplification of the PIK3CA gene have been reported in various types of human cancers. However, little is known about the frequency and prognosis role of PIK3CA activation in nasopharyngeal carcinoma (NPC). This study was conducted with the aim to screen for PIK3CA mutations in the two hot spot regions (exons 9 and 20) and to investigate for the PIK3CA gene amplification combined with the expression analysis of the phosphorylated Akt (pAkt). We showed that among 88 specimens, none had mutation in the helical domain (exon 9) and only one (1.13%) had mutation in the kinase domain (exon 20). On the other hand, PIK3CA gene amplification was found in 21.6% of cases and was strongly associated with distant metastasis (P = 0.002), lymph node involvement (P = 0.032), and advanced tumor stage (P < 0.001). Moreover, patients with PIK3CA copy number gain have a significant reduced overall survival time (P log rank = 0.02). We concluded that PIK3CA gene amplification is frequent in NPC and occurs in the advanced stage of NPC. Moreover, our finding emphasizes the association of PIK3CA gene amplification with worse prognosis in nasopharyngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735264     DOI: 10.1111/j.1349-7006.2009.01292.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  18 in total

1.  An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis.

Authors:  Pamela A Smith; David Merritt; Leah Barr; David A Thorley-Lawson
Journal:  Genes Cancer       Date:  2011-11

2.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

Review 3.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

4.  Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.

Authors:  Wai Kien Yip; Pei Yuan He; Maizaton Atmadini Abdullah; Suryati Yusoff; Heng Fong Seow
Journal:  Pathol Oncol Res       Date:  2015-11-18       Impact factor: 3.201

5.  Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.

Authors:  Toshihito Suda; Takanori Hama; Shu Kondo; Yuki Yuza; Mamoru Yoshikawa; Mitsuyoshi Urashima; Takakuni Kato; Hiroshi Moriyama
Journal:  BMC Cancer       Date:  2012-09-20       Impact factor: 4.430

6.  Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).

Authors:  B B Y Ma; B C Goh; W T Lim; E P Hui; E H Tan; G de Lima Lopes; K W Lo; L Li; H Loong; N R Foster; C Erlichman; A D King; M K M Kam; S F Leung; K C Chan; A T C Chan
Journal:  Invest New Drugs       Date:  2015-06-19       Impact factor: 3.651

7.  Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.

Authors:  Jing Shi; Demao Yao; Wei Liu; Na Wang; Hongjun Lv; Guanjun Zhang; Meiju Ji; Li Xu; Nongyue He; Bingyin Shi; Peng Hou
Journal:  BMC Cancer       Date:  2012-02-01       Impact factor: 4.430

8.  Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers.

Authors:  Warut Tulalamba; Tavan Janvilisri
Journal:  Int J Cell Biol       Date:  2012-03-05

9.  Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand.

Authors:  Arunee Dechaphunkul; Phatcharaporn Thongwatchara; Paramee Thongsuksai; Tanadech Dechaphunkul; Sarayut Lucien Geater
Journal:  J Pathol Transl Med       Date:  2022-02-28

10.  Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.

Authors:  Xiao-jun Qian; Yun-tian Li; Yan Yu; Fen Yang; Rong Deng; Jiao Ji; Lin Jiao; Xuan Li; Rui-Yan Wu; Wen-Dan Chen; Gong-Kan Feng; Xiao-Feng Zhu
Journal:  Oncotarget       Date:  2015-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.